<DOC>
	<DOCNO>NCT01686841</DOCNO>
	<brief_summary>To evaluate safety feasibility reduce human sebum production use ZELTIQ System .</brief_summary>
	<brief_title>A Pilot Clinical Trial Investigating Effect Cutaneous Cooling Sebum Production</brief_title>
	<detailed_description />
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<criteria>Inclusion criterion 1 . Male subject &gt; 18 year age &lt; 25 year age . 2 . Subject average sebum output upper back least 20 , measure sebumeter 3 . Subject Fitzpatrick Skin Phototypes IIII ( see Appendix A ) 4 . Willingness participate study 5 . Willingness receive EXPERIMENTAL treatment 6 . Informed consent agreement sign subject 7 . Willingness follow treatment schedule post treatment care requirement 8 . Willingness use topical systemic retinoids antibiotic course treatment Exclusion criterion 1 . Subject history isotretinoin use 2 . Subject infection dermatologic condition ( aside acne ) area treat 3 . Subject know cold sensitivity disorder include Raynaud 's phenomenon , cold urticaria , cryoglobulinemia , cold induce hemoglobinuria 4 . Presence suntan area treat 5 . Subject immunosuppressed 6 . Subject unable comply treatment , home care followup visit 7 . Subject history vitiligo 8 . Subject history keloid formation 9 . Subject currently enrol clinical study unapproved investigational drug device . 10 . Any condition laboratory value would , professional opinion investigator , potentially affect subject 's response integrity data would pose unacceptable risk subject .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Lipolysis</keyword>
	<keyword>Cryolipolysis</keyword>
	<keyword>Fat Reduction</keyword>
</DOC>